Journal Der Deutschen Dermatologischen Gesellschaft最新文献_第2页

Freie Vorträge 自由演讲

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-29 DOI: 10.1111/ddg.15782_g

引用次数: 0

Poster 海报

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-29 DOI: 10.1111/ddg.15783_g

引用次数: 0

Diaklinik – Interessante Fälle aus der Welt der Dermatologie 皮肤病学的历史：皮肤病学的历史

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-29 DOI: 10.1111/ddg.15781_g

引用次数: 0

Autorenindex Autorenindex

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-29 DOI: 10.1111/ddg.15784_g

引用次数: 0

IL-17 and IL-23 inhibitors dose spacing in adult psoriatic patients: a real-world pilot study. 成年银屑病患者IL-17和IL-23抑制剂剂量间隔：一项现实世界的试点研究

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-26 DOI: 10.1111/ddg.15686

Luca Mastorino, Paolo Dapavo, Michela Ortoncelli, Eleonora Bongiovanni, Pietro Quaglino, Simone Ribero

{"title":"IL-17 and IL-23 inhibitors dose spacing in adult psoriatic patients: a real-world pilot study.","authors":"Luca Mastorino, Paolo Dapavo, Michela Ortoncelli, Eleonora Bongiovanni, Pietro Quaglino, Simone Ribero","doi":"10.1111/ddg.15686","DOIUrl":"https://doi.org/10.1111/ddg.15686","url":null,"abstract":"Background and objectives: De-escalation strategies of biologics in psoriasis treatment are widespread in clinical practice. Dose spacing consists of de-escalating the time range between biological drug injections.Patients and methods: Major objectives were: to describe trends in mean PASI, PASI 100, 90, and ≤ 1 from baseline to 12 months after dose spacing, provide drug survival analysis of dose-spaced regimens, and concurrently describe phenotypic characteristics related to the selection of patient candidates for therapeutic dose spacing. A pre-post analysis was made between mean PASI at dose spacing and baseline, and after 3, 6, 9, and 12 months following dose spacing.Results: Of 1,144 patients treated with IL-23 or IL-17 inhibitors, 61 patients underwent dose spacing. They presented with lower mean baseline Body Mass Index (BMI) (p = 0.011) and PASI (Psoriasis Area Severity Index) (p = 0.044) and were more frequently bio-experienced (p = 0.033). 12 months after dose spacing 42.9%, 85.7%, and 92.9% of observed patients achieved PASI 100, 90, and ≤1. There were no significant differences in mean PASI between dose spacing and subsequent time points. The dose spacing survival was 70% at 1 year.Conclusions: Therapeutic modulation, such as dose spacing, is an effective strategy for most psoriasis patients, resulting in a clear or almost clear skin response that is maintained over time.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toll-like receptor 8 deficiency syndrome result in diffuse pigmented skin rash and autoinflammatory syndrome. toll样受体8缺乏综合征导致弥漫性色素皮疹和自身炎症综合征。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-26 DOI: 10.1111/ddg.15700

Jia-Wei Liu, Dong-Lai Ma

引用次数: 0

Psychosocial distress and persistent adverse events in long-term survivors of stage IV melanoma - a cross-sectional questionnaire study. IV期黑色素瘤长期幸存者的心理社会困扰和持续不良事件——一项横断面问卷研究

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-25 DOI: 10.1111/ddg.15712

Markus Reitmajer, Norbert Schäffeler, Anne Bach, Lena Nanz, Teresa Amaral, Ulrike Leiter, Lukas Flatz, Andrea Forschner

{"title":"Psychosocial distress and persistent adverse events in long-term survivors of stage IV melanoma - a cross-sectional questionnaire study.","authors":"Markus Reitmajer, Norbert Schäffeler, Anne Bach, Lena Nanz, Teresa Amaral, Ulrike Leiter, Lukas Flatz, Andrea Forschner","doi":"10.1111/ddg.15712","DOIUrl":"https://doi.org/10.1111/ddg.15712","url":null,"abstract":"Background: Immune checkpoint inhibitors and targeted therapies have improved survival in patients with stage IV melanoma. However, the challenges faced by long-term survivors remain unclear. The long-term toxicity and psychosocial impact of these treatments in real-world patients have yet to be reported.Material and methods: We conducted a cross-sectional questionnaire study using established screening tools, including the Hornheide Screening Instrument (HSI), the Distress Thermometer (DT) with the National Comprehensive Cancer Network (NCCN) problem list, and melanoma-specific questions addressing persistent adverse events, social impairments, emotional needs, and financial concerns.Results: A total of 159 patients with stage IV melanoma (≥5 years after the initial diagnosis) were enrolled, of whom 93 completed the questionnaire. Approximately one-third of DT/HSI values exceeded the threshold, indicating a need for psycho-oncological support. More than 40% of patients reported persistent treatment-related complaints. Financial and work-related impacts were rare, affecting approximately 8% and 1% of patients, respectively.Conclusions: High rates of psychosocial distress and persistent adverse events were observed, highlighting the need for cancer survivorship programs in the follow-up care of melanoma patients.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asymptomatic verrucous erythematous plaque on the glans. 龟头无症状的疣状红斑斑块。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-25 DOI: 10.1111/ddg.15725

Long Zhang, Wen Ding, Juan Yuan, Chaoxia Peng, Qionghui Cheng, Xia Lei, Nian Chen

引用次数: 0

CDK4/6 inhibitor in combination with aromatase inhibitor effective in metastatic hidradenocarcinoma. CDK4/6抑制剂联合芳香化酶抑制剂治疗转移性汗腺癌有效。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-25 DOI: 10.1111/ddg.15723

Valerie Glatzel, Dirk Tomsitz, Michaela Maurer, Simone Schneider, Stefan Brunner, Nadia Harbeck, Lucie Heinzerling

引用次数: 0

Syphilis in people living with HIV: Diagnostic challenges and specific considerations for individuals without prior HIV infection. 艾滋病毒感染者的梅毒：诊断挑战和对先前没有艾滋病毒感染的个人的具体考虑。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-25 DOI: 10.1111/ddg.15714

Marta Cebolla-Verdugo, Maria Dolores Pegalajar-García, Juan Pablo Velasco-Amador, Ricardo Ruiz-Villaverde

引用次数: 0